Media

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma

Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024

Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis

Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer